378 related articles for article (PubMed ID: 32253470)
1. The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population.
Loudini N; Glaudemans AWJM; Jutte PC; Yakar D; Kwee TC
Skeletal Radiol; 2020 Sep; 49(9):1387-1395. PubMed ID: 32253470
[TBL] [Abstract][Full Text] [Related]
2. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
5. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
6. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
7. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
8. Malignancy rate of biopsied suspicious bone lesions identified on FDG PET/CT.
Adams HJ; de Klerk JM; Heggelman BG; Dubois SV; Kwee TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1231-8. PubMed ID: 26728144
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between
Yu P; Lei J; Xu B; Wang R; Shen Z; Tian J
Acad Radiol; 2020 May; 27(5):682-688. PubMed ID: 31311773
[TBL] [Abstract][Full Text] [Related]
10. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
11. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
14. The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT.
Strobel K; Exner UE; Stumpe KD; Hany TF; Bode B; Mende K; Veit-Haibach P; von Schulthess GK; Hodler J
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2000-8. PubMed ID: 18712385
[TBL] [Abstract][Full Text] [Related]
15. F18-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of vertebral vascular tumors.
Song L; Han S; Jiang L; Zhang W
Clin Imaging; 2020 Sep; 65():24-32. PubMed ID: 32353715
[TBL] [Abstract][Full Text] [Related]
16. Imaging-guided biopsy of (18)F-FDG-avid extrapulmonary lesions: do lesion location and morphologic features on CT affect the positive predictive value for malignancy?
Nguyen ML; Gervais DA; Blake MA; Mueller PR; Sahani DV; Hahn PF; Uppot RN
AJR Am J Roentgenol; 2013 Aug; 201(2):433-8. PubMed ID: 23883226
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of 18F-FDG PET/CT in discriminating between benign and malignant lesions of the ribs.
Choi S; Kim YI; Lee GD; Choi S; Kim HR; Kim YH; Kim DK; Park SI; Ryu JS
Medicine (Baltimore); 2022 Jul; 101(27):e29867. PubMed ID: 35801734
[TBL] [Abstract][Full Text] [Related]
18. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
20. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]